Larry P. Ebbert

1.7k total citations · 1 hit paper
22 papers, 1.3k citations indexed

About

Larry P. Ebbert is a scholar working on Oncology, Physiology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Larry P. Ebbert has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Physiology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Larry P. Ebbert's work include Smoking Behavior and Cessation (5 papers), Lung Cancer Research Studies (4 papers) and Neuroendocrine Tumor Research Advances (2 papers). Larry P. Ebbert is often cited by papers focused on Smoking Behavior and Cessation (5 papers), Lung Cancer Research Studies (4 papers) and Neuroendocrine Tumor Research Advances (2 papers). Larry P. Ebbert collaborates with scholars based in United States, Canada and India. Larry P. Ebbert's co-authors include Wendell Rosse, Richard H. Dixon, Charles L. Loprinzi, Patrick S. Johnson, James E. Krook, J A Mailliard, Loren K. Tschetter, L. Geeraerts, Ann Marie Dose and Neil M. Ellison and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Larry P. Ebbert

22 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Quantitative Determination of Antibody in Idiopathic Thrombocytopenic Purpura

1975 380 citations Richard H. Dixon, Wendell Rosse et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Larry P. Ebbert United States	15	390	382	312	256	178	22	1.3k
M. Horowitz United States	16	269 0.7×	144 0.4×	244 0.8×	266 1.0×	165 0.9×	32	1.2k
Bea C. Tanis Netherlands	23	329 0.8×	321 0.8×	326 1.0×	257 1.0×	82 0.5×	43	1.9k
Peter T. Silberstein United States	21	333 0.9×	159 0.4×	740 2.4×	319 1.2×	172 1.0×	172	1.8k
Richard Brasington United States	22	195 0.5×	170 0.4×	146 0.5×	398 1.6×	158 0.9×	41	1.7k
Arati V. Rao United States	19	402 1.0×	179 0.5×	446 1.4×	173 0.7×	196 1.1×	57	1.2k
Elizabeth A. Manci United States	20	1.3k 3.3×	411 1.1×	100 0.3×	244 1.0×	409 2.3×	52	2.8k
A.J. Gerard Jansen Netherlands	23	657 1.7×	213 0.6×	97 0.3×	201 0.8×	148 0.8×	59	1.6k
Alessandra Spagnoli Italy	24	470 1.2×	221 0.6×	174 0.6×	112 0.4×	222 1.2×	88	1.6k
K A Sobocinski United States	11	618 1.6×	220 0.6×	256 0.8×	55 0.2×	93 0.5×	16	1.7k
Peter Johan Moe Norway	22	387 1.0×	120 0.3×	209 0.7×	208 0.8×	254 1.4×	88	1.7k

Countries citing papers authored by Larry P. Ebbert

Since Specialization

Citations

This map shows the geographic impact of Larry P. Ebbert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Larry P. Ebbert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Larry P. Ebbert more than expected).

Fields of papers citing papers by Larry P. Ebbert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Larry P. Ebbert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Larry P. Ebbert. The network helps show where Larry P. Ebbert may publish in the future.

Co-authorship network of co-authors of Larry P. Ebbert

This figure shows the co-authorship network connecting the top 25 collaborators of Larry P. Ebbert. A scholar is included among the top collaborators of Larry P. Ebbert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Larry P. Ebbert. Larry P. Ebbert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Croghan, Ivana T., R. Douglas Hurt, Shaker R. Dakhil, et al.. (2007). Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings. 82(2). 186–195. 51 indexed citations

2.

Croghan, Ivana T., R. Douglas Hurt, Shaker R. Dakhil, et al.. (2007). Randomized Comparison of a Nicotine Inhaler and Bupropion for Smoking Cessation and Relapse Prevention. Mayo Clinic Proceedings. 82(2). 186–195. 41 indexed citations

3.

Clark, Matthew M., R. Douglas Hurt, Ivana T. Croghan, et al.. (2005). The prevalence of weight concerns in a smoking abstinence clinical trial. Addictive Behaviors. 31(7). 1144–1152. 99 indexed citations

4.

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). Randomized Phase II Study of Daily Versus Continuous-Infusion Schedules of Topotecan in the Treatment of Extensive-Stage Small Cell Lung Cancers. American Journal of Clinical Oncology. 26(3). 236–240. 9 indexed citations

5.

Schaefer, Paul, Randolph S. Marks, Michelle R. Mahoney, et al.. (2003). . American Journal of Clinical Oncology. 26(3). 236–240. 1 indexed citations

6.

Croghan, Gary A., Jeff A. Sloan, Ivana T. Croghan, et al.. (2003). Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: A minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine & Tobacco Research. 5(2). 181–187. 49 indexed citations

7.

Okuno, Scott H., Charles L. Loprinzi, Jeff A. Sloan, et al.. (1999). Phase III Controlled Evaluation of Glutamine for Decreasing Stomatitis in Patients Receiving Fluorouracil (5-FU)-Based Chemotherapy. American Journal of Clinical Oncology. 22(3). 258–261. 68 indexed citations

8.

Burch, Patrick A., Georgene Schroeder, Joseph Rubin, et al.. (1999). North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy. American Journal of Clinical Oncology. 22(5). 505–505. 3 indexed citations

9.

Hartmann, Lynn C., Loren K. Tschetter, Thomas M. Habermann, et al.. (1997). Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia. New England Journal of Medicine. 336(25). 1776–1780. 126 indexed citations

10.

Edmonson, John H., et al.. (1996). Phase II Study of Docetaxel in Advanced Soft Tissue Sarcomas. American Journal of Clinical Oncology. 19(6). 574–576. 48 indexed citations

11.

Long, Harry J., Robert M. Langdon, S. Stephen, et al.. (1995). Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Endometrial Carcinoma. Gynecologic Oncology. 58(2). 240–243. 10 indexed citations

12.

Long, Harry J., H. Samuel Wieand, John W. Kugler, et al.. (1995). Phase II Trial of Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced/Recurrent Carcinoma of the Uterine Cervix and Vagina. Gynecologic Oncology. 57(2). 235–239. 30 indexed citations

13.

Gesme, Dean H., James R. Jett, John Q. Su, et al.. (1993). A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the north central cancer treatment group. Cancer. 71(9). 2723–2726. 15 indexed citations

14.

Veeder, Michael H., James R. Jett, John Q. Su, et al.. (1992). A phase III trial of mitomycin C alone versus mitomycin C, vinblastine, and cisplatin for metastatic squamous cell lung carcinoma. Cancer. 70(9). 2281–2287. 26 indexed citations

15.

Loprinzi, Charles L., Neil M. Ellison, Daniel J. Schaid, et al.. (1990). Controlled Trial of Megestrol Acetate for the Treatment of Cancer Anorexia and Cachexia. JNCI Journal of the National Cancer Institute. 82(13). 1127–1132. 234 indexed citations

16.

Edmonson, J H, Harry S. Wieand, J. W. Kugler, et al.. (1989). Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens. JNCI Journal of the National Cancer Institute. 81(19). 1500–1504. 44 indexed citations

17.

Marschke, Robert F., James N. Ingle, Daniel J. Schaid, et al.. (1989). Randomized clinical trial of CFP versus CMFP in women with metastatic breast cancer. Cancer. 63(10). 1931–1937. 8 indexed citations

18.

Dixon, Richard H., Wendell Rosse, & Larry P. Ebbert. (1975). Quantitative Determination of Antibody in Idiopathic Thrombocytopenic Purpura. New England Journal of Medicine. 292(5). 230–236. 380 indexed citations breakdown →

19.

Mengel, Charles E., et al.. (1969). Relationship between tocopherol status and in vivo hemolysis caused by hyperoxia.. PubMed. 40(2). 132–5. 4 indexed citations

20.

Kann, Herbert E., Charles E. Mengel, W. Delano Meriwether, & Larry P. Ebbert. (1968). Production of In Vitro Lytic Characteristics of Paroxysmal Nocturnal Hemoglobinuria Erythrocytes in Normal Erythrocytes. Blood. 32(1). 49–58. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact